Next Phase Newsletter

A venture capital firm founded in 1988 and headquartered in Taipei, Taiwan is currently investing from its fourth fund of US$27 million that was closed in 2013. Traditionally the firm has been focused on Taiwan-based assets but is now seeking new opportunities from North America and the EU.

Within life sciences, the firm is interested in therapeutics including small molecules, biologics, cell therapy, and gene therapy. The firm is agnostic in terms of indications. The firm prefers early stage assets that have obtained proof-of-concept data in animal models or clinical trials. The firm also considers healthcare services such as hospice and hemodialysis centers.

The firm is looking for competent management teams with sector expertise. After investment, the firm seeks to play an active role in Taiwan-based businesses or to take minority stake in overseas businesses.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A holding company founded in 1962 and based in the Middle East invests in healthcare via an evergreen fund. The firm is a long term equity investor, and prefer to make their first investments into a company in early financing rounds. The firm’s allocations are therefore highly varied in size, from $100,000 to over $40 million throughout the life of an investment; financing is typically provided in tranches with milestone payments. The firm is generally a lead investor, and prefers to take a sizeable minority stake in a portfolio company (20% or more). The firm has the ability to invest globally but focuses on opportunities in Europe and the Middle East. The firm is highly selective regarding investment opportunities.

The firm invests across the medical device sector; the firm is open to considering the full range of device technologies and indications, including both diagnostic devices and devices with a therapeutic purpose. The firm is only interested in devices with the potential to target large markets and create new markets within healthcare; niche products are not of interest.

The firm works alongside medical device incubators, and is open to working with companies as early as the pre-prototype stage. The firm typically exits opportunities at or prior to commercialization stage, so in general market-stage companies are not of interest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based in Sydney, Australia focuses on therapeutics and medical devices that are past pre-clinical trials. The firm currently manages a $2.5 billion evergreen fund, and typically invests between $1 and $10 million. The firm normally makes co-investments in the USA, Europe, Israel, and Australia. The firm does not invest in companies based in Southeast Asia.

The firm is currently looking for new investment opportunities in therapeutics and PMA medical devices. The firm is particularly interested in peripheral blood-based colorectal cancer diagnostics, but is not open to diagnostics in any other subsectors or indications. The firm is open to all subsectors and indications in therapeutics and medical devices, though is not interested in software-enabled devices or lab equipment and drug development enabling technology. The firm does not invest in pre-clinical products, and only seeks products that are either in clinical trials with human data or on the market.

The firm seeks companies with an established management team with experience in the field. The firm does not typically take a board seat after an investment. The firm seeks distribution rights for Australia and Southeast Asia from international companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Canada based venture capital firm looks to make investments of approximately $5 million with reserves left for follow on rounds. The firm looks to make one new equity or debt investment per month and gives preference to companies located in North America but is open to Australia and Western Europe depending on the opportunity. The firm does not request distribution rights for international investments.

The firm is interested in early-stage wearable technology, software-enabled medical devices and any technology that can improve hospital operations. The firm does not have any revenue requirements for wearable technology and the firm is open to regulatory products. The firm is looking for both in-development and clinical stage devices and will consider investments in healthcare IT companies as long as the company is already established with positive cash flow.

The firm values sweat equity but the firm will not make any investments into a company unless the founding team has invested their own funds into the company’s success. The firm takes a board seat when making any new investments and looks for strong, experienced management teams. The first question the firm will ask any new opportunity is whether or not they have experience in marketing, sales, startups, or the industry they are entering. The firm can provide strategic management if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture fund of a multinational healthcare company has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. The fund is an evergreen fund and makes equity investment in early-stage biotech therapeutic and diagnostic companies. The fund prefers Series A. The typical initial investment size ranges from CHF 1-5M with capital reserved for follow-on financing. The fund invests in companies that are based in Europe, North America, and the Pacific Region. The fund is actively seeking new investment opportunities.

The Fund is looking to invest in companies with innovative new technologies, medicines or diagnostics, particularly in the areas of interest to the fund’s parent company. This includes: Oncology, Central Nervous System, Inflammation, Anti-Infectives, Virology, in-Vitro Diagnostics, Diabetes Care, and Molecular Diagnostics. For therapeutic biotech, the fund is willing to invest in companies that are still 18-24 months away from the clinic. The fund highly prefers companies with both a discovery engine and a product pipeline.

The Fund invests in private and public companies. The fund only invests in public companies as part of a collaboration entered into by the parent company’s pharma or diagnostics division. The fund requests board seats and typically prefers to be in an ownership range of 15% or more. In general, the fund prefers to co-invest with leading venture funds as well as other corporate venture funds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global pharmaceutical company is looking to form partnerships with small biotech companies using a variety of structures depending on the needs of the opportunity, including licensing, development partnerships, co-marketing, and acquisitions. Partnerships may also involve in-kind services. The firm works with partners worldwide.

The firm is currently looking opportunistically at novel therapeutic assets. While the firm will consider assets in any indication area, immuno-oncology is an area of high interest; the firm is also particularly interested in other areas of immunology and in inflammation, metabolic disease (particularly type 2 diabetes), fibrosis and hypertension. The firm is open to any type of modality, including small molecules, biologics or cell therapies. The firm also has some interest in companion diagnostics and means of selecting suitable patients or monitoring patients. The firm will work with companies at any stage of development, from very early discoveries through to market.

The firm does not work with companies pursuing incremental innovations; the firm only partners on novel, breakthrough technologies, such as new molecules or new targets. The firm is interested in assets in which the mechanism of action is understood, and it is preferred that the target or pathway of the asset is validated. The firm is interested in assets that have been shown to have an unambiguous advantage, and which can create value for patients and payers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm funded by a single LP based in the Western United States invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $250K to $1M (usually in equity or convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Series A and B financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.

The firm has a focus on the digital health and informatics space, but also invests in novel therapeutics. Generally, the firm focuses on opportunities that avoid or mitigate FDA regulatory risks. The firm is agnostic in terms of subsectors and indications, but does not consider orphan indications. The firm will only consider technologies with proof of concept. Historically, the firm has invested in therapeutics that address oncology, infectious diseases, cardiovascular, and metabolic disorders; drug delivery; orthopedic devices; genomics.

The firm prefers to take a board seat but is generally flexible.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com